Jefferies Raises Price Target on Nektar Therapeutics (NKTR) to $15

November 7, 2016 8:58 AM EST
Get Alerts NKTR Hot Sheet
Price: $12.37 +2.23%

Rating Summary:
    10 Buy, 1 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 11 | Down: 31 | New: 42
Trade NKTR Now!
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.

Jefferies reiterated a Buy on Nektar Therapeutics (NASDAQ: NKTR), and raised the price target to $15.00 (from $14.00), following the company's 3Q earnings report. Based on the recently completed equity offering and mgt’s updated guidance, Jefferies now estimates FY16 & FY17 revenues and EPS of $170M & ($1.17) and $284 & ($0.57) vs $188M & ($1.07) and $303M & ($0.45) respectively.

Analyst David Steinberg commented, "A Q3 EPS loss of $0.32 was largely in-line with our ($0.34) estimate. A significant improvement in gross margin (75% vs 50% JEF) offset slightly lower than projected revenue (-$3M vs our estimate). Importantly, product & royalty income increased $12.8M Y/Y to $20.3M, reflecting NKTR’s growing revenue stream from Movantik and Adynovate. Looking ahead, NKTR has an abundance of key catalysts over the next 6 months."

For an analyst ratings summary and ratings history on Nektar Therapeutics click here. For more ratings news on Nektar Therapeutics click here.

Shares of Nektar Therapeutics closed at $12.30 yesterday.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change

Related Entities

Jefferies & Co, Earnings, Equity Offerings

Add Your Comment